What is the recommended concentration of triamcinolone acetonide (corticosteroid) for intralesional injections in treating facial keloids?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Triamcinolone Concentration for Facial Keloids

For facial keloids, use triamcinolone acetonide at 40 mg/mL concentration, as this is the guideline-recommended dose specifically for hypertrophic scars and keloids. 1

Recommended Concentration and Dosing

  • The American Academy of Dermatology specifically recommends triamcinolone acetonide 40 mg/mL for hypertrophic scars and keloids, which represents the standard of care for these lesions 1

  • The maximum dose per injection session should not exceed 150 mg total 1

  • Injections should be administered every 3-4 weeks as needed 1

Facial-Specific Considerations

Facial skin requires heightened caution due to increased risk of adverse effects. The face is thinner and more prone to steroid-induced atrophy than other body sites, necessitating careful monitoring with repeated injections 2

Dilution Strategy for Facial Use

  • Consider diluting the 40 mg/mL preparation with sterile normal saline to 20 mg/mL or lower for initial facial treatments to balance efficacy with safety, particularly given the higher risk of atrophy and telangiectasia on facial skin 1, 2

  • The British Association of Dermatologists suggests diluting triamcinolone preparations or reducing application frequency while maintaining efficacy 2

Administration Technique

  • Inject just beneath the dermis in the upper subcutis 3

  • Use volumes of 0.05-0.1 mL per injection site to produce localized therapeutic effect 1

  • Blanching at the injection site serves as a useful endpoint indicator 4

  • Use a 23-26 gauge needle for intralesional delivery 4

Expected Outcomes and Monitoring

  • Monotherapy with triamcinolone achieves 50-100% regression of keloids, though recurrence rates are 33% at 1 year and 50% at 5 years 5

  • Monitor closely for skin atrophy, telangiectasia, and pigmentary changes, which are dose-dependent and occur more frequently with repeated injections at higher concentrations 1, 2

  • Atrophy and telangiectasia occur in approximately 37% of patients treated with triamcinolone alone 6

Combination Therapy Considerations

If monotherapy with triamcinolone proves inadequate or causes excessive side effects, consider combination approaches:

  • Triamcinolone 40 mg/mL combined with 5-fluorouracil (3:1 ratio of 5-FU to TAC) demonstrates superior efficacy with fewer adverse effects compared to either agent alone 7, 6

  • Adding platelet-rich plasma to triamcinolone (20 mg/mL) yields better cosmetic outcomes with lower incidence of atrophy and hypopigmentation compared to triamcinolone alone 8

  • Triple therapy with triamcinolone (10 mg/mL) + 5-FU + pulsed-dye laser produces 70% good-to-excellent responses versus 15% with triamcinolone alone 6

Common Pitfalls to Avoid

  • Avoid injection at sites of active infection (impetigo, herpes) 1

  • Do not use in patients with previous hypersensitivity to triamcinolone 1

  • Exercise caution in patients with uncontrolled diabetes, heart failure, or severe hypertension 1

  • Be aware that repeated injections can suppress the hypothalamic-pituitary-adrenal axis 1

  • Facial and intertriginous areas carry higher risk for developing adverse effects, requiring more conservative dosing strategies 1

References

Guideline

Local Injectable Steroids: Recommended Dosing and Administration

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Corticosteroid-Responsive Dermatoses

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

New combination of triamcinolone, 5-Fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2006

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.